Nature Communications (Dec 2019)
Integrated exome and RNA sequencing of dedifferentiated liposarcoma
- Makoto Hirata,
- Naofumi Asano,
- Kotoe Katayama,
- Akihiko Yoshida,
- Yusuke Tsuda,
- Masaya Sekimizu,
- Sachiyo Mitani,
- Eisuke Kobayashi,
- Motokiyo Komiyama,
- Hiroyuki Fujimoto,
- Takahiro Goto,
- Yukihide Iwamoto,
- Norifumi Naka,
- Shintaro Iwata,
- Yoshihiro Nishida,
- Toru Hiruma,
- Hiroaki Hiraga,
- Hirotaka Kawano,
- Toru Motoi,
- Yoshinao Oda,
- Daisuke Matsubara,
- Masashi Fujita,
- Tatsuhiro Shibata,
- Hidewaki Nakagawa,
- Robert Nakayama,
- Tadashi Kondo,
- Seiya Imoto,
- Satoru Miyano,
- Akira Kawai,
- Rui Yamaguchi,
- Hitoshi Ichikawa,
- Koichi Matsuda
Affiliations
- Makoto Hirata
- Laboratory of Genome Technology, Institute of Medical Science, University of Tokyo
- Naofumi Asano
- Division of Rare Cancer Research, National Cancer Center Research Institute
- Kotoe Katayama
- Laboratory of Sequence Analysis, Institute of Medical Science, University of Tokyo
- Akihiko Yoshida
- Department of Pathology and Clinical Laboratory, National Cancer Center Hospital
- Yusuke Tsuda
- Laboratory of Genome Technology, Institute of Medical Science, University of Tokyo
- Masaya Sekimizu
- Department of Clinical Genomics, National Cancer Center Research Institute
- Sachiyo Mitani
- Department of Clinical Genomics, National Cancer Center Research Institute
- Eisuke Kobayashi
- Department of Musculoskeletal Oncology, National Cancer Center Hospital
- Motokiyo Komiyama
- Department of Urology, National Cancer Center Hospital
- Hiroyuki Fujimoto
- Department of Urology, National Cancer Center Hospital
- Takahiro Goto
- Department of Orthopaedic Surgery and Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
- Yukihide Iwamoto
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
- Norifumi Naka
- Musculoskeletal Oncology Service, Osaka International Cancer Institute
- Shintaro Iwata
- Department of Musculoskeletal Oncology, National Cancer Center Hospital
- Yoshihiro Nishida
- Department of Rehabilitation Medicine, Nagoya University Graduate School of Medicine
- Toru Hiruma
- Department of Orthopaedic Surgery, Kanagawa Cancer Center
- Hiroaki Hiraga
- Department of Musculoskeletal Oncology, National Hospital Organization Hokkaido Cancer Center
- Hirotaka Kawano
- Department of Orthopaedic Surgery, Faculty of Medicine, University of Tokyo
- Toru Motoi
- Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
- Yoshinao Oda
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University
- Daisuke Matsubara
- Division of Integrative Pathology, Jichi Medical University
- Masashi Fujita
- Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences
- Tatsuhiro Shibata
- Laboratory of Molecular Medicine, Institiute of Medical Science, University of Tokyo
- Hidewaki Nakagawa
- Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences
- Robert Nakayama
- Department of Orthopaedic Surgery, Keio University School of Medicine
- Tadashi Kondo
- Division of Rare Cancer Research, National Cancer Center Research Institute
- Seiya Imoto
- Division of Health Medical Data Science, Institute of Medical Science, University of Tokyo
- Satoru Miyano
- Laboratory of DNA Information Analysis, Institute of Medical Science, University of Tokyo
- Akira Kawai
- Department of Musculoskeletal Oncology, National Cancer Center Hospital
- Rui Yamaguchi
- Laboratory of DNA Information Analysis, Institute of Medical Science, University of Tokyo
- Hitoshi Ichikawa
- Department of Clinical Genomics, National Cancer Center Research Institute
- Koichi Matsuda
- Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, University of Tokyo
- DOI
- https://doi.org/10.1038/s41467-019-13286-z
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
Understanding the genomic features of dedifferentiated liposarcoma (DDLPS) is likely to uncover new options for management. Here, the authors reveal three prognostic groups, and highlight molecular markers associated with malignant transformation.
